In addition, we analyzed the immune checkpoint PD-1 and CD47 and demonstrated their high expression in tumor tissues compared with normal tissues, which shows the feasibility of anti-PD-1 and anti-CD47 antibodies in the immunotherapy of HCC. The gene discussed is CD47; the disease is hepatocellular carcinoma.